Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.
DermTech, Inc. (symbol: DMTK) is a groundbreaking molecular diagnostic dermatology company dedicated to revolutionizing the diagnosis of skin conditions through innovative non-invasive testing. Located at their CLIA-licensed laboratory in La Jolla, CA, DermTech operates at the cutting edge of dermatological science.
DermTech's core technology focuses on gene expression tests that aid in the clinical diagnosis of skin cancer and other skin conditions. Their flagship product, the Pigmented Lesion Assay (PLA), allows for the analysis of skin biopsy samples using an adhesive patch. This method offers a significant advancement over traditional methods that rely on subjective visual diagnosis and invasive surgical biopsies, which are often prone to error and lead to unnecessary procedures.
The PLA test is designed to detect melanoma in clinically atypical pigmented lesions with high accuracy, providing physicians with critical, objective data to enhance patient care and reduce healthcare costs. By utilizing DermTech’s non-invasive approach, patients experience enhanced comfort and safety during the diagnostic process.
DermTech is committed to advancing the field of dermatology through continuous innovation. In addition to their focus on skin cancer, the company is developing genomic tests to diagnose inflammatory skin diseases and conditions related to aging. These efforts are aimed at providing comprehensive solutions that improve the accuracy of diagnoses and overall patient outcomes.
With a strong emphasis on scientific development and patient care, DermTech partners with various healthcare providers and institutions to expand the availability of their tests. The company generates revenue through their laboratory services, ensuring a sustainable business model while aiming for growth and expanded impact in the dermatology field.
DermTech (NASDAQ: DMTK) announced key leadership appointments, including Loren Clarke, M.D. as Chief Medical Officer, Ray Bassi as Vice President of Sales, and Patrick Johnson as Vice President of IT and Digital Systems. Dr. Clarke brings extensive experience in dermatopathology, and Bassi has over 25 years in sales, previously with Dermira. Johnson has a strong background in IT leadership. This strategic move aims to enhance DermTech's mission in precision dermatology, focusing on non-invasive genomic testing, improving patient care, and supporting commercial growth initiatives.
DermTech, Inc. (NASDAQ: DMTK) announced the expansion of its Scientific Advisory Board with the addition of Dr. Klaus Busam, Dr. Joslyn Kirby, and Dr. Justin Ko. These industry leaders bring extensive experience in dermatology, dermatopathology, and genomics, enhancing DermTech's mission of transforming dermatology through its non-invasive skin genomics platform. The new members aim to support innovation and development in technologies impacting dermatological diseases. CEO John Dobak expressed optimism about their contributions to advance precision diagnostics and treatment options.
DermTech (NASDAQ: DMTK) announced its participation in upcoming investor conferences. The company will present at the 41st Annual William Blair Growth Stock Conference on June 1, 2021, at 4:20 PM ET, with a live webcast available on its website. DermTech will also attend the 18th Annual Craig-Hallum Institutional Investor Conference on June 2, 2021. DermTech leads in precision dermatology, utilizing a non-invasive skin genomics platform to enhance skin cancer detection and treatment personalization. More details can be found on DermTech’s investor relations site.
DermTech (NASDAQ: DMTK) reported Q1 2021 results highlighting a 175% increase in assay revenue to $2.2 million and a 62% total revenue increase to $2.5 million. Billable sample volume rose 62% to approximately 9,400. For the first time, the company achieved a positive assay gross margin of 10%, significantly up from -46% in Q1 2020. Despite these gains, a net loss of $15.1 million was reported, reflecting increased operational expenses. Management forecasts Q2 2021 assay revenue between $2.4 million and $2.8 million.
DermTech, Inc. (NASDAQ: DMTK) announced that its management will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 4:00 p.m. Eastern Time. Interested individuals can access a live webcast and an archived version for 30 days post-event through the DermTech website.
DermTech is a leader in precision dermatology, utilizing a non-invasive skin genomics platform to enhance the detection of skin cancers and other diseases. Their innovative approach aims to democratize access to high-quality dermatology care.
DermTech, Inc. (NASDAQ: DMTK) recently presented at the 2021 Society for Investigational Dermatology (SID) virtual meeting. Chief Scientific Officer Michael Howell, PhD, discussed a study on Atopic Dermatitis (AD) that utilizes DermTech's non-invasive skin sampling technology. The research aims to better stratify AD patients based on their inflammatory signatures, which may lead to improved personalized treatments. DermTech is also initiating a prospective study to evaluate biologic treatments for AD. Current therapies are effective for less than 50% of patients, indicating a significant need for innovation.
DermTech (NASDAQ: DMTK) has launched the #Stickit2Melanoma campaign to raise awareness about skin exams during Melanoma Awareness Month. The initiative aims to encourage proactive skin health checks, as 1 in 5 Americans develop skin cancer by age 70. DermTech pledges up to $1 million over four years to donate $5 for each skin exam scheduled under the campaign. Early detection can lead to a 99% survival rate for localized melanoma. The campaign reflects DermTech's commitment to reducing melanoma deaths through its non-invasive testing technology.
DermTech, Inc. (NASDAQ: DMTK) will release its Q1 2021 financial results on May 13, 2021, after market closure. A conference call and webcast will follow at 1:30 p.m. Pacific time. Interested individuals can participate via telephone or through the company's website. DermTech is focused on precision dermatology, utilizing a non-invasive skin genomics platform to enhance skin cancer detection and treatment customization. The company emphasizes accessibility to quality dermatological care.
DermTech (NASDAQ: DMTK) has announced a collaboration with Stanford University School of Medicine to study biomarkers in Hidradenitis Suppurativa (HS), a chronic skin condition. The three-year research aims to enhance understanding and treatment of HS using DermTech's non-invasive genomics platform. This partnership emphasizes DermTech’s mission to improve patient outcomes in dermatology through advanced genomic techniques. The study is crucial as HS often remains undiagnosed for over seven years, highlighting the urgent need for better diagnostic methods.
DermTech, Inc. (NASDAQ: DMTK) has launched the DermTech PLAplus test, enhancing melanoma detection through TERT promoter DNA analysis. This advancement raises the sensitivity of the test from 91% to 97%, while maintaining a negative predictive value of over 99%. The introduction of PLAplus aids in early diagnosis, vital for improving patient outcomes. Recognized by the NCCN guidelines, DermTech’s non-invasive genomic testing leverages over 21 peer-reviewed studies and supports clinical decision-making for suspicious skin lesions.
FAQ
What is the current stock price of DermTech (DMTK)?
What is the market cap of DermTech (DMTK)?
What does DermTech, Inc. specialize in?
How does DermTech's Pigmented Lesion Assay (PLA) work?
Where is DermTech, Inc. located?
What makes DermTech's diagnostic method unique?
What other skin conditions does DermTech focus on?
How does DermTech improve patient care?
Is DermTech's technology widely available?
How does DermTech generate revenue?
What is DermTech's mission?
What recent achievements has DermTech made?
